Skip to main content
Erschienen in: Pituitary 6/2014

01.12.2014

Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth

verfasst von: Yakun Yang, Miaomiao Sheng, Fengming Huang, Dechao Bu, Xiaohai Liu, Yong Yao, Congxin Dai, Bowen Sun, Jindong Zhu, Yonghui Jiao, Zhenqing Wei, Huijuan Zhu, Lin Lu, Yi Zhao, Chengyu Jiang, Renzhi Wang

Erschienen in: Pituitary | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Adrenocorticotrophic hormone (ACTH)-dependent Cushing’s syndrome, called Cushing disease, is caused by a corticotroph tumor of the pituitary gland. Insulin-like growth factor binding protein 6 (IGFBP6), which regulates insulin-like growth factor (IGF) activity and inhibits several IGF2-dependent cancer growths, plays a pivotal role in the tumorigenesis of malignancy, but its roles in ACTH-secreting pituitary adenomas remain unclear.

Objective

To investigate IGFBP6 expression in ACTH-secreting pituitary adenomas, and its involvement in tumor growth.

Methods

Sporadic ACTH-secreting pituitary adenomas specimens (n = 41) and adjacent non-tumorous pituitary tissues (n = 9) were collected by transphenoidal surgery. IGFBP6 expression was assessed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and validated by Western blotting. Associations of IGFBP6 expression with maximum tumor diameter or Ki-67 labeling index were evaluated in ACTH-secreting pituitary adenomas.

Results

IGFBP6 mRNA and protein expression were both decreased in ACTH-secreting pituitary adenomas, compared to adjacent non-tumorous pituitary tissues (P < 0.01). IGFBP6 expression was correlated inversely with maximum tumor diameter (Rho = −0.53, P < 0.0001) and Ki-67 levels (Rho = −0.52, P < 0.05). Moreover, IGFBP6 downregulation activated PI3 K-AKT-mTOR pathway in ACTH-secreting pituitary adenomas.

Conclusions

IGFBP6 attenuation in ACTH-secreting pituitary adenomas is associated with tumor growth, through activation of PI3K-AKT-mTOR pathway. The finding underlies IGFBP6 roles in Cushing disease and would potentially provide a novel target of medical therapies.
Literatur
2.
Zurück zum Zitat Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96:195–208PubMedCrossRef Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96:195–208PubMedCrossRef
3.
Zurück zum Zitat Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462PubMedCentralPubMedCrossRef Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Kaptain GJ, Vincent DA, Sheehan JP, Laws ER Jr (2008) Transsphenoidal approaches for the extracapsular resection of midline suprasellar and anterior cranial base lesions. Neurosurgery 62:1264–1271PubMedCrossRef Kaptain GJ, Vincent DA, Sheehan JP, Laws ER Jr (2008) Transsphenoidal approaches for the extracapsular resection of midline suprasellar and anterior cranial base lesions. Neurosurgery 62:1264–1271PubMedCrossRef
5.
Zurück zum Zitat Gadelha M, Neto LV. (2014) Efficacy of medical treatment in Cushing's disease: a systematic review. Clin Endocrinol (Oxf) 80:1–12 Gadelha M, Neto LV. (2014) Efficacy of medical treatment in Cushing's disease: a systematic review. Clin Endocrinol (Oxf) 80:1–12
6.
Zurück zum Zitat Bach LA (2005) IGFBP-6 five years on; not so ‘forgotten’? Growth Horm IGF Res 15:185–192PubMedCrossRef Bach LA (2005) IGFBP-6 five years on; not so ‘forgotten’? Growth Horm IGF Res 15:185–192PubMedCrossRef
7.
Zurück zum Zitat Toretsky JA, Helman LJ (1996) Involvement of IGF-II in human cancer. J Endocrinol 149:367–372PubMedCrossRef Toretsky JA, Helman LJ (1996) Involvement of IGF-II in human cancer. J Endocrinol 149:367–372PubMedCrossRef
8.
Zurück zum Zitat Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW (1997) Gene expression profiles in normal and cancer cells. Science 276:1268–1272PubMedCrossRef Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW (1997) Gene expression profiles in normal and cancer cells. Science 276:1268–1272PubMedCrossRef
9.
Zurück zum Zitat Gallicchio MA, Kneen M, Hall C, Scott AM, Bach LA (2001) Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int J Cancer 94:645–651PubMedCrossRef Gallicchio MA, Kneen M, Hall C, Scott AM, Bach LA (2001) Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int J Cancer 94:645–651PubMedCrossRef
10.
Zurück zum Zitat Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854PubMedCrossRef Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854PubMedCrossRef
11.
Zurück zum Zitat Gallicchio MA, Kaun C, Wojta J, Binder B, Bach LA (2003) Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. J Cell Physiol 197:131–138PubMedCrossRef Gallicchio MA, Kaun C, Wojta J, Binder B, Bach LA (2003) Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. J Cell Physiol 197:131–138PubMedCrossRef
12.
Zurück zum Zitat Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM (2000) Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19:4432–4436PubMedCrossRef Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM (2000) Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19:4432–4436PubMedCrossRef
13.
Zurück zum Zitat Vogel T (2013) Insulin/IGF-signalling in embryonic and adult neural proliferation and differentiation in the mammalian central nervous system. doi:10.5772/54946 Vogel T (2013) Insulin/IGF-signalling in embryonic and adult neural proliferation and differentiation in the mammalian central nervous system. doi:10.​5772/​54946
14.
Zurück zum Zitat Werner H, Weinstein D, Bentov I (2008) Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 114:17–22PubMedCrossRef Werner H, Weinstein D, Bentov I (2008) Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 114:17–22PubMedCrossRef
15.
Zurück zum Zitat Fumagalli L, Campa CC, Germena G, Lowell CA, Hirsch E, Berton G (2013) Class I phosphoinositide-3-kinases and SRC kinases play a nonredundant role in regulation of adhesion-independent and -dependent neutrophil reactive oxygen species generation. J Immunol 190:3648–3660PubMedCrossRef Fumagalli L, Campa CC, Germena G, Lowell CA, Hirsch E, Berton G (2013) Class I phosphoinositide-3-kinases and SRC kinases play a nonredundant role in regulation of adhesion-independent and -dependent neutrophil reactive oxygen species generation. J Immunol 190:3648–3660PubMedCrossRef
17.
Zurück zum Zitat Yamada S, Fukuhara N, Nishioka H, Takeshita A, Inoshita N, Ito J, Takeuchi Y (2012) Surgical management and outcomes in patients with Cushing disease with negative pituitary magnetic resonance imaging. World Neurosurg 77:525–532PubMedCrossRef Yamada S, Fukuhara N, Nishioka H, Takeshita A, Inoshita N, Ito J, Takeuchi Y (2012) Surgical management and outcomes in patients with Cushing disease with negative pituitary magnetic resonance imaging. World Neurosurg 77:525–532PubMedCrossRef
18.
Zurück zum Zitat Mampalam TJ, Wilson CB (1988) Transsphenoidal microsurgery for cushing disease a report of 216 cases. Ann Intern Med 109(6):487–493PubMedCrossRef Mampalam TJ, Wilson CB (1988) Transsphenoidal microsurgery for cushing disease a report of 216 cases. Ann Intern Med 109(6):487–493PubMedCrossRef
19.
Zurück zum Zitat Kiehna EN, Keil M, Lodish M, Stratakis C, Oldfield EH (2010) Pseudotumor cerebri after surgical remission of Cushing’s disease. J Clin Endocrinol Metab 95:1528–1532PubMedCentralPubMedCrossRef Kiehna EN, Keil M, Lodish M, Stratakis C, Oldfield EH (2010) Pseudotumor cerebri after surgical remission of Cushing’s disease. J Clin Endocrinol Metab 95:1528–1532PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Monteith SJ, Starke RM, Jane JA Jr, Oldfield EH (2012) Use of the histological pseudocapsule in surgery for Cushing disease: rapid postoperative cortisol decline predicting complete tumor resection. J Neurosurg 116:721–727PubMedCrossRef Monteith SJ, Starke RM, Jane JA Jr, Oldfield EH (2012) Use of the histological pseudocapsule in surgery for Cushing disease: rapid postoperative cortisol decline predicting complete tumor resection. J Neurosurg 116:721–727PubMedCrossRef
22.
Zurück zum Zitat Jagannathan J, Smith R, DeVroom HL, Vortmeyer AO, Stratakis CA, Nieman LK, Oldfield EH (2009) Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg 111:531–539PubMedCentralPubMedCrossRef Jagannathan J, Smith R, DeVroom HL, Vortmeyer AO, Stratakis CA, Nieman LK, Oldfield EH (2009) Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J Neurosurg 111:531–539PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Vance ML (2003) Perioperative management of patients undergoing pituitary surgery. Endocrinol Metab Clin North Am 32:355–365PubMedCrossRef Vance ML (2003) Perioperative management of patients undergoing pituitary surgery. Endocrinol Metab Clin North Am 32:355–365PubMedCrossRef
24.
Zurück zum Zitat Kato M, Ishizaki A, Hellman U, Wernstedt C, Kyogoku M, Miyazono K, Heldin CH, Funa K (1995) A human keratinocyte cell line produces two autocrine growth inhibitors, transforming growth factor-beta and insulin-like growth factor binding protein-6, in a calcium- and cell density-dependent manner. J Biol Chem 270:12373–12379PubMedCrossRef Kato M, Ishizaki A, Hellman U, Wernstedt C, Kyogoku M, Miyazono K, Heldin CH, Funa K (1995) A human keratinocyte cell line produces two autocrine growth inhibitors, transforming growth factor-beta and insulin-like growth factor binding protein-6, in a calcium- and cell density-dependent manner. J Biol Chem 270:12373–12379PubMedCrossRef
26.
Zurück zum Zitat Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540PubMedCentralPubMedCrossRef Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Aghi MK (2008) Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 4:560–568PubMedCrossRef Aghi MK (2008) Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrinol Metab 4:560–568PubMedCrossRef
28.
Zurück zum Zitat Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761–787PubMed Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761–787PubMed
29.
Zurück zum Zitat Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMed Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMed
30.
Zurück zum Zitat Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG (1996) Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28:619–637PubMedCrossRef Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG (1996) Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28:619–637PubMedCrossRef
31.
Zurück zum Zitat Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801–831PubMed Rajaram S, Baylink DJ, Mohan S (1997) Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801–831PubMed
32.
Zurück zum Zitat Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, Seke Etet PF (2013) Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 20:R1–R17PubMedCrossRef Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, Seke Etet PF (2013) Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 20:R1–R17PubMedCrossRef
33.
Zurück zum Zitat Koyama N, Zhang J, Huqun, Miyazawa H, Tanaka T, Su X, Hagiwara K (2008) Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B. Oncogene 27:6581–6589PubMedCrossRef Koyama N, Zhang J, Huqun, Miyazawa H, Tanaka T, Su X, Hagiwara K (2008) Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B. Oncogene 27:6581–6589PubMedCrossRef
34.
Zurück zum Zitat Kuo YS, Tang YB, Lu TY, Wu HC, Lin CT (2010) IGFBP-6 plays a role as an oncosuppressor gene in NPC pathogenesis through regulating EGR-1 expression. J Pathol 222:299–309PubMedCrossRef Kuo YS, Tang YB, Lu TY, Wu HC, Lin CT (2010) IGFBP-6 plays a role as an oncosuppressor gene in NPC pathogenesis through regulating EGR-1 expression. J Pathol 222:299–309PubMedCrossRef
35.
Zurück zum Zitat Martins AS, Olmos D, Missiaglia E, Shipley J (2011) Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011:209736PubMedCentralPubMedCrossRef Martins AS, Olmos D, Missiaglia E, Shipley J (2011) Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011:209736PubMedCentralPubMedCrossRef
Metadaten
Titel
Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth
verfasst von
Yakun Yang
Miaomiao Sheng
Fengming Huang
Dechao Bu
Xiaohai Liu
Yong Yao
Congxin Dai
Bowen Sun
Jindong Zhu
Yonghui Jiao
Zhenqing Wei
Huijuan Zhu
Lin Lu
Yi Zhao
Chengyu Jiang
Renzhi Wang
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 6/2014
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0535-8

Weitere Artikel der Ausgabe 6/2014

Pituitary 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.